(2S)-2′-Methoxykurarinone (MK), a compound isolated from the roots of Sophora flavescens, has various physiological properties, such as anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. However, the effect of S. flavescens-derived MK on osteoclastogenesis remains unknown. Therefore, we examined the effect and mechanism of action of MK on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation and bone resorption. MK inhibited osteoclast differentiation in bone marrow cell-osteoblast cocultures but did not affect the RANKL-to-osteoprotegerin ratio induced by osteoclastogenic factors in osteoblasts. MK also inhibited RANKL-induced osteoclast differentiation from bone marrow macrophages in a dose-dependent manner, without cytotoxicity. Pretreatment with MK significantly suppressed the Akt, p38, c-Jun N terminal kinase (JNK), c-Fos, and nuclear factor of activated T cells c1 (NFATc1) pathways and inhibited the bone-resorbing activity of mature osteoclasts. These results collectively suggest that MK inhibits osteoclast differentiation and bone resorption through RANKL-induced mitogen-activated protein kinases (MAPKs) and c-Fos-NFATc1 signaling pathways.
Key words (2S)-2′-methoxykurarinone; bone resorption; osteoclast; osteoporosis; receptor activator of nuclear factor-κB ligand (RANKL)Osteoclasts, which originate from hematopoietic cells of the monocyte macrophage lineage, play a crucial role in bone remodeling.1,2) The bone loss in many important skeletal disorders, such as osteoporosis, rheumatoid arthritis, and bone metastases, occurs mainly because of increased osteoclast activity.3,4) Bone formation is regulated by osteoblasts, which also express the receptor activator of nuclear factor kappa-B ligand (RANKL), which has been identified as a member of the tumor necrosis factor (TNF) superfamily and regulates osteoclast differentiation through cell-to-cell contact.3,4) Osteoblasts and stromal cells also produce a soluble decoy receptor for RANKL, osteoprotegerin (OPG), which inhibits osteoclast formation by interrupting the interaction between RANKL and RANK, resulting in an increase in bone density and bone volume.1,2) Several osteoclastogenic factors, such as 1,25-dihydroxyvitamin D 3 (VitD 3 ) and proinflammatory cytokines, can stimulate osteoclast formation by up-regulating the ratio of RANKL to OPG in osteoblasts or stromal cells.